Self-modulation of neocortical pyramidal neurons by endocannabinoids

Nat Neurosci. 2009 Dec;12(12):1488-90. doi: 10.1038/nn.2430. Epub 2009 Nov 15.

Abstract

Control of pyramidal neuron excitability is vital for the functioning of the neocortex. Somatodendritic slow self-inhibition (SSI) allows inhibitory neurons to regulate their own activity, but the existence of similar mechanisms in excitatory cells has not been shown. We found that in rodents endocannabinoids mediated SSI and long-term modulation of inhibitory connections in layer 2/3 pyramidal neurons with a distinct dendritic morphology, suggesting that a glutamatergic network in cortical circuits is self-regulated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzoxazines / pharmacology
  • Cannabinoid Receptor Modulators / metabolism*
  • Cannabinoids / pharmacology
  • Dendrites / physiology
  • Endocannabinoids*
  • Glutamic Acid / physiology
  • Mice
  • Morpholines / pharmacology
  • Naphthalenes / pharmacology
  • Neocortex / cytology*
  • Neural Inhibition / physiology*
  • Organ Culture Techniques
  • Patch-Clamp Techniques
  • Pyramidal Cells / drug effects*
  • Pyramidal Cells / metabolism*
  • Pyramidal Cells / ultrastructure
  • Rats
  • Receptor, Cannabinoid, CB1 / agonists
  • Receptor, Cannabinoid, CB1 / physiology
  • gamma-Aminobutyric Acid / physiology

Substances

  • Benzoxazines
  • Cannabinoid Receptor Modulators
  • Cannabinoids
  • Endocannabinoids
  • Morpholines
  • Naphthalenes
  • Receptor, Cannabinoid, CB1
  • Glutamic Acid
  • gamma-Aminobutyric Acid
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone